tumor associated antigen specific cytotoxic t lymphocytes
Cell therapyexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2012 (NCT01333046)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, passive
Tumor antigens immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tumor associated antigen specific cytotoxic t lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06193759 | Phase 1 | Sep 20, 2024 | Georgetown University |
| NCT03093350 | Phase 2 | Aug 1, 2017 | Baylor University, Methodist Cancer Center, Houston, Texas, National Cancer Institute (NCI), State of Texas |
| NCT02239861 | Phase 1 | Apr 1, 2015 | Baylor University, Methodist Cancer Center, Houston, Texas, Pierce Phillips Charity |
| NCT02291848 | Phase 1 | Apr 1, 2015 | Baylor University, Methodist Cancer Center, Houston, Texas |
| NCT01333046 | Phase 1 | Jan 1, 2012 | Baylor University, Methodist Cancer Center, Houston, Texas, National Cancer Institute (NCI) |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 4 | 4 | 2 | 2012 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 4 | 0 | 2 | 2012 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2012 |
| Georgetown University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Pierce Phillips Charity | Academic/Hospital | 1 | 0 | 1 | 2015 |
| State of Texas | Government | 1 | 0 | 1 | 2017 |
6 organizations
Page 1 / 1